Among patients with idiopathic pulmonary fibrosis, the antifibrotic medications pirfenidone and nintedanib were associated with significantly reduced risks for all-cause mortality and hospitalizations vs. those who received no treatment, according to data published in the American Journal of Respiratory and Critical Care Medicine.
Pirfenidone (Esbriet, Genentech) and nintedanib (Ofev, Boehringer Ingelheim) received FDA approval to treat IPF in 2014 based on clinical trials showing that they slowed decline in lung function and may improve survival.
American Thoracic Society Conference
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.